| Dr Anand Patel, MD | |
|
1701 S Creasy Ln, Lafayette, IN 47905-4972 | |
| (765) 502-4000 | |
| (765) 502-4709 |
| Full Name | Dr Anand Patel |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 19 Years |
| Location | 1701 S Creasy Ln, Lafayette, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346361904 | NPI | - | NPPES |
| 201049660 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | IP917 (Kentucky) | Secondary |
| 207R00000X | Internal Medicine | 01068937A (Indiana) | Secondary |
| 208M00000X | Hospitalist | 01068937A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Lafayette | Lafayette, IN | Hospital |
| Franciscan Health Crawfordsville | Crawfordsville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Physician Network | 3072790682 | 989 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | Johnson Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346248986 PECOS PAC ID: 8527972595 Enrollment ID: O20040316000585 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | University Family Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043275787 PECOS PAC ID: 7911992797 Enrollment ID: O20040420000393 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | Baptist Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508269200 PECOS PAC ID: 5597867184 Enrollment ID: O20090527000129 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | Bluegrass Kidney Consultants Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558500918 PECOS PAC ID: 0840357646 Enrollment ID: O20100114000013 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | Franciscan Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | Post Acute Care Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609268259 PECOS PAC ID: 5698092732 Enrollment ID: O20150330000164 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Entity Name | Hospitalist Physicians Of Indiana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306576277 PECOS PAC ID: 1052795986 Enrollment ID: O20220826000967 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Anand Patel, MD Po Box 781076, Detroit, MI 48278-9819 Ph: (317) 528-4800 | Dr Anand Patel, MD 1701 S Creasy Ln, Lafayette, IN 47905-4972 Ph: (765) 502-4000 |
News Archive
Patients with acute stroke who receive stroke-unit care are less likely to die or become disabled than patients treated in a conventional hospital ward, according to an observational follow-up study published in this week's issue of The Lancet.
The Center for Global Health Policy's "Science Speaks" blog interviews Kenneth Mayer, founding medical research director of Fenway Health, as part of its "Blueprint" series, which examines issues surrounding the creation of a blueprint for an AIDS-free generation commissioned by Secretary of State Hillary Clinton in July.
The film "Avatar" isn't the only 3-D blockbuster making a splash this winter. A team of Houston scientists this week unveiled a new technique for growing 3-D cell cultures, a technological leap from the flat petri dish that could save millions of dollars in drug-testing costs. The research is reported in Nature Nanotechnology.
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.
› Verified 9 days ago
Ryan I Deweese, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-838-4698 | |
Dr. Kaushal Narayanbhai Patel, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-838-4698 | |
Christopher A Mansfield, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-838-4698 | |
Dr. Abdul K Sankari, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1701 S Creasy Ln, Lafayette, IN 47905 Phone: 765-502-4000 Fax: 765-502-4709 | |
Dr. Mark H Williams, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2525 South St, Lafayette, IN 47904 Phone: 765-807-2320 Fax: 765-807-2330 | |
Eva Bartaula, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1701 S Creasy Ln, Lafayette, IN 47905 Phone: 765-502-4000 Fax: 765-502-4709 | |
Na Zhu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 5165 Mccarty Lane, Lafayette, IN 47905 Phone: 765-448-8000 |